Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BeiGene, Ltd. (ONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ONC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $357.27
1 Year Target Price $357.27
| 15 | Strong Buy |
| 8 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.41% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 37.47B USD | Price to earnings Ratio - | 1Y Target Price 357.27 |
Price to earnings Ratio - | 1Y Target Price 357.27 | ||
Volume (30-day avg) 24 | Beta 0.27 | 52 Weeks Range 170.99 - 321.69 | Updated Date 08/15/2025 |
52 Weeks Range 170.99 - 321.69 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.2591 | Actual 0.84 |
Profitability
Profit Margin -3.89% | Operating Margin (TTM) 6.68% |
Management Effectiveness
Return on Assets (TTM) -1.06% | Return on Equity (TTM) -4.98% |
Valuation
Trailing PE - | Forward PE 121.95 | Enterprise Value 35735187450 | Price to Sales(TTM) 8.21 |
Enterprise Value 35735187450 | Price to Sales(TTM) 8.21 | ||
Enterprise Value to Revenue 7.83 | Enterprise Value to EBITDA 400.38 | Shares Outstanding 110029000 | Shares Floating 872842210 |
Shares Outstanding 110029000 | Shares Floating 872842210 | ||
Percent Insiders 17.24 | Percent Institutions 35.75 |
Upturn AI SWOT
BeiGene, Ltd.
Company Overview
History and Background
BeiGene, Ltd. was founded in 2010. It is a global biotechnology company focused on developing and commercializing innovative cancer medicines.
Core Business Areas
- Research and Development: Discovery and preclinical/clinical development of novel oncology therapeutics.
- Manufacturing: Manufacturing of clinical and commercial drug supplies.
- Commercialization: Sales and marketing of approved products in various global markets.
Leadership and Structure
John V. Oyler (Co-Founder, Chairman, and CEO) leads BeiGene. The company has a matrix organizational structure with functional departments supporting product development and commercialization across multiple geographies.
Top Products and Market Share
Key Offerings
- Brukinsa (zanubrutinib): A BTK inhibitor approved for various B-cell malignancies. Revenue in 2023 was approximately $1.3 billion. Competitors include Imbruvica (ibrutinib) by AbbVie and Janssen, and Calquence (acalabrutinib) by AstraZeneca.
- Tislelizumab (anti-PD-1 antibody): An anti-PD-1 antibody approved in China and other regions for various solid tumors. Competitors include Keytruda (pembrolizumab) by Merck and Opdivo (nivolumab) by Bristol Myers Squibb.
Market Dynamics
Industry Overview
The oncology market is a large and growing market driven by increasing cancer incidence and advancements in treatment options. Immunotherapies and targeted therapies are major growth drivers.
Positioning
BeiGene is positioned as an innovative oncology company with a focus on developing and commercializing differentiated therapies. Its competitive advantage lies in its strong R&D capabilities and global footprint.
Total Addressable Market (TAM)
The global oncology market is expected to reach $500 billion by 2030. BeiGene is positioned to capture a significant share through its pipeline and commercial efforts.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global commercial presence
- Experienced management team
- Innovative therapies
Weaknesses
- High operating expenses
- Dependence on key products
- Limited profitability
- Competition from established players
Opportunities
- Expansion into new markets
- Strategic collaborations
- Acquisition of new technologies
- Development of new therapies
Threats
- Regulatory hurdles
- Patent expirations
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- AZN
- MRK
- BMY
Competitive Landscape
BeiGene faces competition from established pharmaceutical companies with larger resources and broader product portfolios. However, BeiGene's innovative therapies and global footprint provide a competitive advantage.
Major Acquisitions
Impact Biomedicines
- Year: 2019
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquired global rights to develop and commercialize fedratinib (later sold to Sanofi).
Growth Trajectory and Initiatives
Historical Growth: BeiGene has experienced significant revenue growth in recent years, driven by the commercial success of Brukinsa and tislelizumab.
Future Projections: Analysts project continued revenue growth driven by further expansion of Brukinsa and tislelizumab, as well as potential approvals of new therapies. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Brukinsa, advancing the clinical development of new pipeline candidates, and establishing strategic collaborations.
Summary
BeiGene is a growing biotechnology company with a strong pipeline of oncology therapeutics and a global commercial presence. The company is still unprofitable due to high R&D and commercialization costs but shows strong revenue growth. The company needs to focus on cost management while continuing to innovate. Competition is fierce within the Oncology market, but BeiGene has a unique portfolio of drugs in the pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
Disclaimers:
This analysis is based on available data and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeiGene, Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-02-03 | Co-Founder, Executive Chairman & CEO Mr. John V. Oyler | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11000 | Website https://beonemedicines.com |
Full time employees 11000 | Website https://beonemedicines.com | ||
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.